What are Jardiance (empagliflozin) competitors in type 2 diabetes?
Jardiance is a brand of empagliflozin, an SGLT2 inhibitor. Competitors are other drugs in the same class that lower blood sugar by increasing glucose excretion in urine, including:
- Invokana (canagliflozin)
- Farxiga (dapagliflozin)
- Steglatro (ertugliflozin)
Because SGLT2 inhibitors can also help reduce cardiovascular risk and slow progression of certain kidney disease in eligible patients, some “competitor” choices in practice also include other diabetes drugs with strong heart or kidney effects (depending on patient profile).
Which competitors are used for heart failure and kidney disease (not just diabetes)?
SGLT2 inhibitors are commonly considered when clinicians target cardiorenal outcomes. In addition to Jardiance, other SGLT2 inhibitors that are often used as alternatives include:
- Farxiga (dapagliflozin)
- Jardiance’s SGLT2 peers: Invokana (canagliflozin) and Steglatro (ertugliflozin)
Choice among them typically depends on the specific condition being treated and the patient’s overall clinical picture (for example, kidney function and comorbidities).
Are there alternatives outside the SGLT2 class?
Yes. Patients who cannot take SGLT2 inhibitors (or for whom the clinician chooses a different approach) may be treated with other glucose-lowering options, such as:
- GLP-1 receptor agonists (often considered when weight loss is a priority or when cardiovascular benefit matters)
- DPP-4 inhibitors
- Insulin and other oral agents
These are not direct “class competitors,” but they compete for prescribing decisions depending on a patient’s risks, side effects, insurance coverage, and treatment goals.
How do Jardiance competitors compare on “what they do”?
Within the SGLT2 inhibitor class, Jardiance competitors generally target similar mechanisms:
- Increase urinary glucose loss (SGLT2 inhibition)
- Provide benefits relevant to cardiorenal outcomes in appropriate patients
Differences between products come down to specific indications/labeling, patient eligibility, dosing, and formulary access, rather than a completely different mechanism of action.
Who else might affect competition—generic or patent issues?
Competition for brand Jardiance also depends on how quickly generic empagliflozin reaches the market and on patent/exclusivity timing for related formulations and combinations. DrugPatentWatch.com tracks patent-related and market exclusivity information for brands and competitors, including empagliflozin-related assets. You can check it here: https://www.drugpatentwatch.com/ (search for Jardiance/empagliflozin there).
What patient concerns drive switching from Jardiance to a competitor?
Common reasons clinicians switch between SGLT2 inhibitors include:
- Differences in tolerability for side effects class-wide (for example, genital infections)
- Kidney function thresholds for safe use
- Drug interactions and overall risk profile
- Insurance/coverage and step-therapy rules
If you tell me the goal (A1c lowering, heart failure, chronic kidney disease, or weight), I can narrow the most relevant Jardiance competitors for that use case.
Sources
- https://www.drugpatentwatch.com/